Recent Press Releases

Prosthetic Heart Valves - Global Trends, Estimates and Forecasts, 2012-2018

DUBLIN, Dec. 10, 2014 /PRNewswire/ --Research and Markets

Mylan Launches One of First Available Generic Versions of Celebrex(R) Capsules

PITTSBURGH, Dec. 10, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic...

Teva Announces Launch of First Generic Celebrex® Capsules in the United States

JERUSALEM--(BUSINESS WIRE)--Dec. 10, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex® (Celecoxib) Capsules in...

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS

INDIANAPOLIS, Dec.

Takeda reports Phase III AETHERA clinical trial data from ADCETRIS® at ASH annual meeting

Takeda UK Ltd reports data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as...

FERRING PHARMACEUTICALS TO ACQUIRE MARKETING RIGHTS FOR DDAVP® (DESMOPRESSIN) PRODUCT PORTFOLIO FROM SANOFI

PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is...

Merck Statement Regarding CUBICIN Patent Litigation

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of...

MOVENTIG® APPROVED IN THE EUROPEAN UNION FOR OPIOID-INDUCED CONSTIPATION

First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives AstraZeneca today announced that MOVENTIG® (naloxegol) has...

Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant

TH

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight®...

GVK Biosciences Media Update

This is an update to the letter from the France's ANSM to the MAHs dated 23rd October 2014 regarding the concerns raised by ANSM over the check-out ECG's conducted at GVK BIO's Clinical facility,...

FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for...

Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash

Acquisition Augments Merck's Strong Foundation and Opportunity for Growth in Hospital Acute Care Market Monday, December 8, 2014 7:00 am EST KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS...

VENABLE VICTORIOUS IN NEXIUM REVERSE PAYMENT CASE

VENABLE VICTORIOUS IN NEXIUM REVERSE PAYMENT CASE Boston, MA, December 5, 2014…Venable scored an important victory today in Federal District Court in Boston on behalf of its client, Ranbaxy,...

JURY VERDICT FAVOURS ASTRAZENECA IN NEXIUM ANTITRUST LITIGATION

JURY VERDICT FAVOURS ASTRAZENECA IN NEXIUM ANTITRUST LITIGATION 5 December 2014 AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict...

Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle

THO

KKR to Invest in Arbor Pharmaceuticals

ATLANTA & NEW YORK--(BUSINESS WIRE)-- Arbor Pharmaceuticals ("Arbor"), a specialty pharmaceutical company, today announced that KKR, a leading global investment firm, is acquiring a...

Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

MHRA and other EU Member States Issue Positive Assessment Report under the Decentralized Procedure for New, Three-Times-A-Week COPAXONE® 40 mg/ml Formulation JERUSALEM--(BUSINESS WIRE)--Dec. 4,...

Impact of Malnutrition in U.S. at $157 Billion Annually

Study shows greatest cost linked to people with depression, COPD, coronary artery disease and dementia

ABBOTT PARK, Ill., Dec.